{"id":1027835,"date":"2024-02-27T18:02:49","date_gmt":"2024-02-27T18:02:49","guid":{"rendered":"https:\/\/magazineoffice.com\/roche-pone-fin-a-una-mala-compra-costosa\/"},"modified":"2024-02-27T18:02:52","modified_gmt":"2024-02-27T18:02:52","slug":"roche-pone-fin-a-una-mala-compra-costosa","status":"publish","type":"post","link":"https:\/\/magazineoffice.com\/roche-pone-fin-a-una-mala-compra-costosa\/","title":{"rendered":"Roche pone fin a una mala compra costosa"},"content":{"rendered":"
\n<\/p>\n
Roche pag\u00f3 una vez m\u00e1s de ocho mil millones de d\u00f3lares por el medicamento Esbriet. Pero las altas expectativas no se cumplieron. La empresa ahora est\u00e1 considerando una venta.<\/p>\n<\/p><\/div>\n<\/div>\n